Pharmacokinetic Study of AVI-4065 in Cerebral Spinal Fluid Among Healthy Adult Males Following Subcutaneous Administration.

Trial Profile

Pharmacokinetic Study of AVI-4065 in Cerebral Spinal Fluid Among Healthy Adult Males Following Subcutaneous Administration.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2012

At a glance

  • Drugs AVI 4065 (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Sarepta Therapeutics
  • Most Recent Events

    • 02 Aug 2012 Trial company changed from AVI BioPharma to Sarepta Therapeutics as reported by ClinicalTrials.gov.
    • 20 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top